Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + liposomal doxorubicin + ifosfamide
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy consists of the PD-1 inhibitor tislelizumab, the anthracycline liposomal doxorubicin (PLD), and the alkylating agent ifosfamide. It is being investigated as a first-line treatment for specific subtypes of unresectable or metastatic soft tissue sarcoma. Tislelizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, enhancing T-cell anti-tumor activity. Liposomal doxorubicin provides a sustained release of doxorubicin, which intercalates into DNA and inhibits topoisomerase II, while ifosfamide causes DNA cross-linking. The combination aims to leverage the immunogenic cell death induced by chemotherapy to enhance the efficacy of the checkpoint inhibitor.
- Other names
- Tislelizumab + PLD + IFOTislelizumab + Pegylated Liposomal Doxorubicin + Ifosfamide
02
Targets
TOP2A (DNA topoisomerase II)DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tislelizumab + liposomal doxorubicin + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + liposomal doxorubicin + ifosfamide.